Leading-Edge Psychedelic Treatments for Mental Illness and Neurological Disorders

Pharmaceutical Investing

Orphan Drug Development an Exciting Opportunity to Provide Superior Therapeutics, Lobe Sciences CEO Says

Psychedelics Investing

“It's an exciting opportunity for us to go after patients that have also been neglected by Big Pharma, and it gives us the opportunity to take advantage of an opening where we think we can provide superior therapeutics,” said Lobe Sciences Chairman and CEO Philip J. Young.

Lobe Sciences (CSE:LOBE,OTCQB:LOBEF) has significantly expanded its portfolio following its acquisition of Altemia & Company. The purchase also sets Lobe Sciences up for revenue generation in the short term, helping secure funds for orphan drug research and development, according to Philip Young, chairman and CEO.

The acquisition gives Lobe Sciences access to the intellectual property and commercial inventory for Altemia, a medical food for the management of sickle cell disease.

“Our team, via the medical food, are putting the plans in place right now, and we've identified potential partners for distribution, which is very important in this marketplace,” Young said. “And we've done the initial clinical research demonstrating that it's better at reducing a biomarker of inflammation, which is a core component of sickle cell. So we have the data necessary and the product necessary to begin selling it into the marketplace.”

Sickle cell disease is a rare blood disorder affecting approximately 100,000 patients in the US, and millions more across the globe, according to Young.

Watch the full interview with Lobe Sciences chairman and CEO Philip J. Young above.

Disclaimer: This interview is sponsored by Lobe Sciences (CSE:LOBE,OTCQB:LOBEF). This interview provides information which was sourced by the Investing News Network (INN) and approved by Lobe Sciences in order to help investors learn more about the company. Lobe Sciences is a client of INN. The company’s campaign fees pay for INN to create and update this interview.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Lobe Sciences and seek advice from a qualified investment advisor.

This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.

LOBE:CNX

Psychedelics Investing cse stocks cse:lobe lobe sciences Pharmaceutical Investing

MARKETS

Markets
TSX	19920.31	+146.23
TSXV	604.09	+1.45
DOW	33093.34	+328.69
S&P 500	4205.45	+54.17
NASD	12975.69	+277.59
ASX	7154.80	+16.60

COMMODITIES

Commodities
Gold	1945.24	+1.21
Silver	23.23	-0.06
Copper	3.68	+0.09
Palladium	1713.17	0.00
Platinum	1087.26	0.00
Oil	73.28	+1.45
Heating Oil	2.37	+0.03
Natural Gas	2.43	+0.12

DOWNLOAD FREE REPORTS

BROWSE COMPANIES BY SECTOR